ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer

• Published in: Human vaccines & immunotherapeutics Vol. 17; no. 8; pp. 2617 - 2625
• Main Authors: Galicia-Carmona, Tatiana, Arango-Bravo, Eder, Serrano-Olvera, Juan a, Flores-de La Torre, Celia, Cruz-Esquivel, Ivan, Villalobos-Valencia, Ricardo, Morán-Mendoza, Andrés, Castro-Eguiluz, Denisse, Cetina-Pérez, Lucely
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 03-08-2021; Taylor & Francis Group
• Subjects: ADXS11-001; Cancer Vaccines; cervical cancer; Female; Humans; Immunotherapy; Listeria monocytogenes; listeria monocytogenes vaccine; Mini-Review; Papillomavirus Infections - therapy; Uterine Cervical Neoplasms - therapy; Vaccines, Attenuated; listeria monocytogenes vaccine; cervical cancer; ADXS11-001; Immunotherapy
• ISSN: 2164-5515; 2164-554X
• DOI: 10.1080/21645515.2021.1893036

Human papillomavirus (HPV) infection is a well-known cause of cervical cancer. Therapeutic cancer vaccines are part of the current therapeutic options for HPV-associated cancers. Axalimogen filolisbac (ADXS11-001) is an immunotherapy based on live attenuated Listeria monocytogenes-listeriolysin O (Lm-LLO), designed by biological engineering to secrete an antigen-adjuvant fusion protein, composed of a truncated fragment of LLO fused to HPV. The proposed mechanism of action is that Lm-based vectors infect antigen-presenting cells (APC) and secrete HPV-LLO fusion proteins within the APC cytoplasm, these proteins are processed and presented to cytotoxic T lymphocytes (CTL), thus generating a new population of CTLs specific to HPV antigens. These HPV-specific CTLs destroy HPV infected cells. ADXS11-001 has demonstrated safety results in phase I-II studies in women with cervical cancer and is being assessed in clinical trials in patients with HPV-positive anal canal and head and neck cancers.